• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    1/18/24 8:05:59 AM ET
    $ADAG
    $ARAV
    $ATRC
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADAG alert in real time by email

    Gainers

    • Celularity (NASDAQ:CELU) shares rose 43.4% to $0.27 during Thursday's pre-market session. The company's market cap stands at $52.3 million.
    • Kronos Bio (NASDAQ:KRON) stock moved upwards by 33.64% to $1.43. The company's market cap stands at $83.3 million.
    • Jin Medical International (NASDAQ:ZJYL) shares rose 24.82% to $122.0. The market value of their outstanding shares is at $954.9 million.
    • Telesis Bio (NASDAQ:TBIO) stock moved upwards by 20.33% to $0.38. The market value of their outstanding shares is at $11.3 million.
    • Lipocine (NASDAQ:LPCN) shares increased by 18.7% to $4.57. The company's market cap stands at $24.2 million.
    • Lucid Diagnostics (NASDAQ:LUCD) stock rose 16.0% to $1.68. The market value of their outstanding shares is at $72.1 million.

    Losers

    • Aravive (NASDAQ:ARAV) stock fell 50.5% to $0.05 during Thursday's pre-market session. The company's market cap stands at $4.0 million.
    • AtriCure (NASDAQ:ATRC) shares fell 34.16% to $22.0. The company's market cap stands at $1.0 billion.
    • Processa Pharma (NASDAQ:PCSA) shares decreased by 18.29% to $0.22. The market value of their outstanding shares is at $5.4 million.
    • Humana (NYSE:HUM) stock declined by 14.24% to $384.0. The market value of their outstanding shares is at $47.2 billion.
    • Mesoblast (NASDAQ:MESO) stock fell 12.07% to $1.53. The market value of their outstanding shares is at $131.2 million.
    • Adagene (NASDAQ:ADAG) stock decreased by 9.76% to $3.61. The market value of their outstanding shares is at $158.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADAG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADAG
    $ARAV
    $ATRC
    $CELU

    CompanyDatePrice TargetRatingAnalyst
    AtriCure Inc.
    $ATRC
    2/18/2026Outperform → Perform
    Oppenheimer
    Humana Inc.
    $HUM
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    AtriCure Inc.
    $ATRC
    2/11/2026$36.00Overweight → Neutral
    Analyst
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Humana Inc.
    $HUM
    1/7/2026$290.00Overweight → Equal Weight
    Wells Fargo
    Humana Inc.
    $HUM
    12/5/2025$313.00Hold → Buy
    Jefferies
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    Adagene Inc.
    $ADAG
    11/24/2025$9.00Buy
    Guggenheim
    More analyst ratings

    $ADAG
    $ARAV
    $ATRC
    $CELU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer Ventura Joseph C converted options into 1,035 units of Humana Common and covered exercise/tax liability with 478 units of Humana Common, increasing direct ownership by 3% to 17,087 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/26/26 5:09:07 PM ET
    $HUM
    Medical Specialities
    Health Care

    President, Insurance Renaudin George Ii covered exercise/tax liability with 419 units of Humana Common and converted options into 1,035 units of Humana Common, increasing direct ownership by 4% to 16,075 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/26/26 3:43:58 PM ET
    $HUM
    Medical Specialities
    Health Care

    SVP, Chief Accting Off & Cont. Felter John-Paul W. was granted 5,669 units of Humana Common, converted options into 165 units of Humana Common and covered exercise/tax liability with 84 units of Humana Common, increasing direct ownership by 332% to 7,484 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 4:04:34 PM ET
    $HUM
    Medical Specialities
    Health Care

    $ADAG
    $ARAV
    $ATRC
    $CELU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AtriCure downgraded by Oppenheimer

    Oppenheimer downgraded AtriCure from Outperform to Perform

    2/18/26 7:52:06 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    Humana downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Humana from Outperform to Sector Perform and set a new price target of $189.00

    2/12/26 8:16:45 AM ET
    $HUM
    Medical Specialities
    Health Care

    AtriCure downgraded by Analyst with a new price target

    Analyst downgraded AtriCure from Overweight to Neutral and set a new price target of $36.00

    2/11/26 7:49:25 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ADAG
    $ARAV
    $ATRC
    $CELU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ryoncil® Profits Underpinning Substantial Growth Pipeline

    NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 (H1 FY2026). FINANCIAL HIGHLIGHTS FOR H1 FY20261 Performance driven by successful commercial launch of Ryoncil® Total revenue of US$51.3 million (A$78.3 million),2 up from US$3.2 million.Successful U.S. commercial launch of Ryoncil® (remestemcel-L-rknd) generated gross sales of US$57.0 million and revenue of US$48.7 million after gross to net adjustment.Ryoncil® gross profit, excluding amortization, was US$44.2 million versus nil in

    2/26/26 7:42:54 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Humana Inc. to Present at the 2026 Leerink Partners Global Healthcare Conference

    Humana Inc. (NYSE:HUM) announced today that Jim Rechtin, President and Chief Executive Officer, and Celeste Mellet, Chief Financial Officer, will make a presentation to investors at the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 10:40 a.m. Eastern time. A live audio webcast of the presentation will be available via Humana's Investor Relations page at https://humana.gcs-web.com/. The company suggests webcast participants sign on approximately 15 minutes in advance of the presentation to allow time to run a system test and download any free software needed for access purposes. About Humana Humana (NYSE:HUM) is a leading U.S. healthcare company. Through

    2/26/26 4:15:00 PM ET
    $HUM
    Medical Specialities
    Health Care

    AtriCure to Participate in the Citizens Life Sciences Conference

    AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Citizens Life Sciences Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, March 10, 2026, at 1:05 p.m. Eastern Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more tha

    2/24/26 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ADAG
    $ARAV
    $ATRC
    $CELU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TESTOSTERONE UNDECANOATE issued to LIPOCINE INC

    Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    3/29/22 4:34:43 AM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Tentative Approval for TESTOSTERONE UNDECANOATE

    Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Tentative Approval' on 12/08/2020. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form

    12/20/20 4:30:41 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ARAV
    $ATRC
    $CELU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    Director Matheis Dennis bought $101,840 worth of shares (100,000 units at $1.02), increasing direct ownership by 18% to 665,443 units (SEC Form 4)

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    8/22/25 5:17:58 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Amendment: Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31), increasing direct ownership by 40% to 565,443 units (SEC Form 4)

    4/A - Lucid Diagnostics Inc. (0001799011) (Issuer)

    5/23/25 4:14:42 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $ADAG
    $ARAV
    $ATRC
    $CELU
    SEC Filings

    View All

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    2/27/26 9:18:59 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    2/27/26 6:11:44 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Lipocine Inc.

    424B5 - Lipocine Inc. (0001535955) (Filer)

    2/26/26 5:33:06 PM ET
    $LPCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADAG
    $ARAV
    $ATRC
    $CELU
    Leadership Updates

    Live Leadership Updates

    View All

    Humana Announces Insurance Leadership Transition

    George Renaudin to Retire as Insurance Segment President by Q3 2026 Aaron Martin to Join as President of Medicare Advantage and Insurance Segment President Successor John Barger to Succeed Martin as President of Medicare Advantage Humana Inc. (NYSE:HUM) today announced that George Renaudin, Insurance Segment President and member of Humana's Enterprise Leadership Team, will retire by Q3 2026 following a successful 29-year career at the company. During this period, Renaudin played a pivotal role in establishing and growing Humana's Medicare Advantage and Medicaid programs, helping to build them into high-performing businesses and assembling a strong insurance leadership team. "George has co

    12/16/25 8:05:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $ADAG
    $ARAV
    $ATRC
    $CELU
    Financials

    Live finance-specific insights

    View All

    Humana Board Declares Payment of Quarterly Dividend to Stockholders

    Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 24, 2026 to stockholders of record as of the close of business on March 27, 2026. About Humana Humana (NYSE:HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large.

    2/19/26 6:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results

    Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year Full Year 2025 net loss of $11.4 million and positive adjusted EBITDA of $61.8 million 2025 growth marked by expanding use of new products, including cryoSPHERE® MAX™ and AtriClip FLEX-Mini®, and the continued adoption of EnCompass® clamp AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-o

    2/17/26 4:01:00 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    Humana Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Financial Guidance

    Reports 4Q25 net loss per share of $6.61 on a GAAP basis, Adjusted net loss per share of $3.96; reports full year (FY) 2025 earnings per share (EPS) of $9.84 on a GAAP basis, $17.14 on an Adjusted basis; quarterly and FY Adjusted results in line with management's expectations 4Q25 Insurance segment GAAP benefit ratio of 93.1 percent; FY 2025 Insurance segment GAAP benefit ratio of 90.4 percent, slightly better than guidance of 'the top end of the range of 90.1 percent to 90.5 percent' Introduces FY 2026 GAAP EPS guidance of 'at least $8.89'; 'at least $9.00' on an Adjusted basis; the anticipated year-over-year decline results from the Star Ratings headwind for Bonus Year 2026, net of

    2/11/26 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $ADAG
    $ARAV
    $ATRC
    $CELU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.

    SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    12/12/24 4:30:32 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by AtriCure Inc.

    SC 13G - AtriCure, Inc. (0001323885) (Subject)

    11/14/24 8:00:04 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care